TherapeuticsMD, Inc. (TXMD)
NASDAQ: TXMD · Real-Time Price · USD
1.090
+0.010 (0.93%)
Sep 5, 2025, 12:22 PM - Market open

TherapeuticsMD Statistics

Total Valuation

TherapeuticsMD has a market cap or net worth of $12.62 million. The enterprise value is $13.04 million.

Market Cap12.62M
Enterprise Value 13.04M

Important Dates

The last earnings date was Tuesday, August 12, 2025, after market close.

Earnings Date Aug 12, 2025
Ex-Dividend Date n/a

Share Statistics

TherapeuticsMD has 11.57 million shares outstanding. The number of shares has increased by 2.98% in one year.

Current Share Class 11.57M
Shares Outstanding 11.57M
Shares Change (YoY) +2.98%
Shares Change (QoQ) +0.19%
Owned by Insiders (%) 1.61%
Owned by Institutions (%) 12.35%
Float 9.56M

Valuation Ratios

PE Ratio n/a
Forward PE n/a
PS Ratio 4.87
Forward PS n/a
PB Ratio 0.46
P/TBV Ratio 0.54
P/FCF Ratio 14.93
P/OCF Ratio 14.93
PEG Ratio n/a
Financial Ratio History

Enterprise Valuation

EV / Earnings n/a
EV / Sales 5.09
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF 15.57

Financial Position

The company has a current ratio of 2.89, with a Debt / Equity ratio of 0.24.

Current Ratio 2.89
Quick Ratio 2.10
Debt / Equity 0.24
Debt / EBITDA n/a
Debt / FCF 7.89
Interest Coverage n/a

Financial Efficiency

Return on equity (ROE) is -1.98% and return on invested capital (ROIC) is -4.11%.

Return on Equity (ROE) -1.98%
Return on Assets (ROA) -3.61%
Return on Invested Capital (ROIC) -4.11%
Return on Capital Employed (ROCE) -6.72%
Revenue Per Employee $2.56M
Profits Per Employee -$459,000
Employee Count1
Asset Turnover 0.07
Inventory Turnover n/a

Taxes

Income Tax -63,000
Effective Tax Rate n/a

Stock Price Statistics

The stock price has decreased by -39.66% in the last 52 weeks. The beta is 0.51, so TherapeuticsMD's price volatility has been lower than the market average.

Beta (5Y) 0.51
52-Week Price Change -39.66%
50-Day Moving Average 1.14
200-Day Moving Average 1.14
Relative Strength Index (RSI) 43.71
Average Volume (20 Days) 17,003

Short Selling Information

The latest short interest is 24,546, so 0.21% of the outstanding shares have been sold short.

Short Interest 24,546
Short Previous Month 20,818
Short % of Shares Out 0.21%
Short % of Float 0.26%
Short Ratio (days to cover) 1.03

Income Statement

In the last 12 months, TherapeuticsMD had revenue of $2.56 million and -$459,000 in losses. Loss per share was -$0.04.

Revenue2.56M
Gross Profit 2.56M
Operating Income -2.27M
Pretax Income -6.13M
Net Income -459,000
EBITDA -1.89M
EBIT -2.27M
Loss Per Share -$0.04
Full Income Statement

Balance Sheet

The company has $6.07 million in cash and $6.60 million in debt, giving a net cash position of -$535,000 or -$0.05 per share.

Cash & Cash Equivalents 6.07M
Total Debt 6.60M
Net Cash -535,000
Net Cash Per Share -$0.05
Equity (Book Value) 27.29M
Book Value Per Share 2.36
Working Capital 8.80M
Full Balance Sheet

Cash Flow

Operating Cash Flow 837,000
Capital Expenditures n/a
Free Cash Flow 837,000
FCF Per Share $0.07
Full Cash Flow Statement

Margins

Gross margin is 100.00%, with operating and profit margins of -88.82% and -17.94%.

Gross Margin 100.00%
Operating Margin -88.82%
Pretax Margin -23.72%
Profit Margin -17.94%
EBITDA Margin -73.70%
EBIT Margin -88.82%
FCF Margin 32.71%

Dividends & Yields

TherapeuticsMD does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Years of Dividend Growth n/a
Payout Ratio n/a
Buyback Yield -2.98%
Shareholder Yield -2.98%
Earnings Yield -3.67%
FCF Yield 6.70%
Dividend Details

Analyst Forecast

Price Target n/a
Price Target Difference n/a
Analyst Consensus n/a
Analyst Count n/a
Revenue Growth Forecast (5Y) n/a
EPS Growth Forecast (5Y) n/a
Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value n/a
Lynch Upside n/a
Graham Number n/a
Graham Upside n/a

Stock Splits

The last stock split was on May 9, 2022. It was a reverse split with a ratio of 1:50.

Last Split Date May 9, 2022
Split Type Reverse
Split Ratio 1:50

Scores

TherapeuticsMD has an Altman Z-Score of -33.64 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score -33.64
Piotroski F-Score 4